VHL and clear cell renal carcinoma: Currently, there is only one drug that directly targets the HIFα subunit in clinical use: the HIF-2 dimerization inhibitor belzutifan, which is used to treat HIF-2 prevalent VHL-deficient clear cell renal cell carcinoma [57].